Clinical trial
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and…
NCT00167986 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00167986 |
|---|---|
| Title | Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care |
| Official title | Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Escherichia Coli Infections, Klebsiella Infections |
| Intervention type | Drug |
| Interventions | vancomycin-resistant enterococci and ESBL |
| Enrollment | 480 |
| Start date | Jan 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Mar 15, 2007 |
| Countries | South Korea |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: